エピソード

  • 6: Expanding Options in mHSPC: What the Latest FDA Approval Means for Clinical Practice

    6: Expanding Options in mHSPC: What the Latest FDA Approval Means for Clinical Practice
    2025/12/03
    Panelists discuss how the recent FDA approval of darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC) expands treatment options, offering improved tolerability with lower fatigue rates and fewer central nervous system adverse effects than other androgen pathway inhibitors, while exploring considerations for patient selection, trial design interpretation, and the evolving role of real-world evidence in clinical decision-making.
    続きを読む 一部表示
    39 分
  • 4: Pharmacists at the Forefront: Advancing Care for Patients with ROS1+ NSCLC

    4: Pharmacists at the Forefront: Advancing Care for Patients with ROS1+ NSCLC
    2025/10/15
    This video explores the evolving treatment landscape for ROS1-positive non-small cell lung cancer (NSCLC), focusing on targeted therapies, clinical evidence for repotrectinib, management of adverse events, and the pharmacist’s role in improving patient care and adherence.
    続きを読む 一部表示
    1 時間 3 分
  • 3: Pharmacists at the Forefront: Advancing Care for Patients with ROS1+ NSCLC

    3: Pharmacists at the Forefront: Advancing Care for Patients with ROS1+ NSCLC
    2025/10/15
    1 時間 3 分
  • 2: Pharmacists at the Forefront: Advancing Care for Patients with ROS1+ NSCLC

    2: Pharmacists at the Forefront: Advancing Care for Patients with ROS1+ NSCLC
    2025/10/15
    This video explores the evolving treatment landscape for ROS1-positive non-small cell lung cancer (NSCLC), focusing on targeted therapies, clinical evidence for repotrectinib, management of adverse events, and the pharmacist’s role in improving patient care and adherence.
    続きを読む 一部表示
    1 時間 3 分
  • 1: Redefining Response in mHSPC: Ultralow PSA, Treatment Nuance, and the Call for More Equitable Care

    1: Redefining Response in mHSPC: Ultralow PSA, Treatment Nuance, and the Call for More Equitable Care
    2025/10/01
    Jack R. Andrews, MD; Alicia Morgans, MD, MPH; and Murilo de Almeida Luz, MD, discuss how ultralow prostate-specific antigen thresholds (below 0.02) serve as important prognostic biomarkers in metastatic hormone-sensitive prostate cancer, with recent post hoc analyses from the ARANOTE trial showing that patients achieving these ultralow levels with combination androgen deprivation therapy plus darolutamide therapy have significantly better radiographic progression-free survival and time to castration-resistant disease compared with those who don't reach these thresholds.
    続きを読む 一部表示
    31 分
  • Redefining Response in mHSPC: Ultralow PSA, Treatment Nuance, and the Call for More Equitable Care

    Redefining Response in mHSPC: Ultralow PSA, Treatment Nuance, and the Call for More Equitable Care
    2025/10/01
    Jack R. Andrews, MD; Alicia Morgans, MD, MPH; and Murilo de Almeida Luz, MD, discuss how ultralow prostate-specific antigen thresholds (below 0.02) serve as important prognostic biomarkers in metastatic hormone-sensitive prostate cancer, with recent post hoc analyses from the ARANOTE trial showing that patients achieving these ultralow levels with combination androgen deprivation therapy plus darolutamide therapy have significantly better radiographic progression-free survival and time to castration-resistant disease compared with those who don't reach these thresholds.
    続きを読む 一部表示
    39 分
  • Exploring the Role of IL-13 Inhibition in AD: Clinical Perspectives & Practical Applications

    Exploring the Role of IL-13 Inhibition in AD: Clinical Perspectives & Practical Applications
    2025/09/29
    A pair of leading subject matter experts discuss the current landscape of atopic dermatitis, including unmet needs, and the role of IL-13 inhibition in the management.
    続きを読む 一部表示
    48 分
  • Empowering Pharmacists in the Management of Patients With Urothelial Cancer

    Empowering Pharmacists in the Management of Patients With Urothelial Cancer
    2025/09/03
    Sherry Vogt, PharmD, BCOP; and Megan Hinkley, PharmD, MBA, BCOP, discuss how pharmacists play a crucial role in managing patients with bladder cancer through treatment selection, patient education, adverse effect monitoring, and the evolving landscape of therapies including traditional chemotherapy, immunotherapy, and antibody-drug conjugates like enfortumab vedotin plus pembrolizumab.
    続きを読む 一部表示
    46 分